



ASX / MEDIA RELEASE

27th January 2017

SARAH Study Awarded Oral Abstract at Upcoming EASL/ILC Meeting

Sydney, Australia; 27th January 2017 – Sirtex Medical Limited (ASX:SRX) is pleased to announce that the SARAH randomised controlled clinical study results will be presented at the upcoming European Association for the Study of the Liver, International Liver Congress™ (EASL/ILC) in Amsterdam, the Netherlands from 19th-23rd April 2017.

The SARAH study has been awarded an Oral Abstract (denoted GS-010) at the meeting and will be presented in the General Session III on Saturday, 22nd April 2017 between 10am-12pm local time. The oral abstract is entitled “SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma.”

Unless the abstract is embargoed, the SARAH study abstract will be released on the 5th of April at 10 a.m. Central European Time (CET), at which time Sirtex will make a further ASX announcement.

Mr Nigel Lange, Interim CEO of Sirtex Medical commented “We are delighted the landmark SARAH study has been awarded an Oral Abstract at ILC 2017, and eagerly await the presentation of the study results.”

The SARAH study directly compared SIR-Spheres® Y-90 resin microspheres versus the current standard-of-care systemic therapy sorafenib (Nexavar®, Bayer Healthcare Pharmaceuticals) in patients with non-resectable advanced hepatocellular carcinoma (HCC), also known as primary liver cancer. The primary endpoint of the SARAH study is Overall Survival (OS) with secondary endpoints including safety and tolerability, Progression-Free Survival (PFS), tumour response rates, quality of life scores and overall healthcare costs between the two arms of the study.

SARAH is the largest randomised study ever to compare Selective Internal Radiation Therapy using SIR-Spheres microspheres against the standard-of-care systemic therapy in the treatment of HCC.

About SARAH

SARAH (Sorafenib versus Radioembolisation in Advanced Hepatocellular carcinoma) is a Phase III multi-centre prospective randomised open-label study for patients in France with advanced HCC (Barcelona Clinic Liver Cancer stage C) with or without portal vein thrombosis and no extrahepatic spread, or whose disease has progressed or recurred after previous therapies; and who are ineligible for surgical resection, ablation or liver transplantation.

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

The primary goal of the SARAH study is to assess if radioembolisation with SIR-Spheres Y-90 resin microspheres provides an increased survival benefit compared to sorafenib in patients with advanced HCC. The study is also comparing the quality of life of patients and other measures such as the tolerability of the treatments and healthcare costs associated with each intervention. For more information on the SARAH study, please visit: <http://clinicaltrials.gov/ct2/show/NCT01482442>

About Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC) is the most common form of primary liver cancer – cancer that starts in the liver. It is the sixth most common cancer in the world and the second most common cause of cancer-related death¹.

About SIR-Spheres[®] Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, directly to liver tumours. SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union and Australia.

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Over 73,000 doses have been supplied to treat patients with liver cancer at more than 1,000 medical centres in over 40 countries. For more information please visit www.sirtex.com.

For further information please contact:

Investor Enquiries:

Mr Nigel Lange
Interim CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

SIR-Spheres[®] is a registered trademark of Sirtex SIR-Spheres Pty Ltd

¹ GLOBOCAN 2012. Estimated cancer mortality, incidence and prevalence worldwide.
<http://globocan.iarc.fr/Default.aspx>